Celldex Therapeutics Inc.

Celldex Therapeutics Inc.

CLDX

Market Cap$1.36B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Celldex Therapeutics Inc.Celldex Therapeutics Inc.-8.3--21%--
$-1.14

Current Fair Value

105.6% downside

Overvalued by 105.6% based on the discounted cash flow analysis.

Share Statistics

Market cap$1.36 Billion
Enterprise Value$1.33 Billion
Dividend Yield$0 (0%)
Earnings per Share$-2.45
Beta1.76
Outstanding Shares64,395,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-8.33
PEG-82.54
Price to Sales-
Price to Book Ratio1.86
Enterprise Value to Revenue133.42
Enterprise Value to EBIT-8.66
Enterprise Value to Net Income-9
Total Debt to Enterprise0
Debt to Equity0.01

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Celldex Therapeutics Inc.

CEO: Anthony Marucci

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeu...